# A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies

> **NCT01930552** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 20 (actual)

## Conditions studied

- Neoplasm Malignant

## Interventions

- **DRUG:** Aflibercept AVE0005
- **DRUG:** Leucovorin
- **DRUG:** Irinotecan
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT01930552
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01930552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01930552, "A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01930552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*